Complete response of lung metastases from rectal cancer to combination first‑line therapy of S‑1 and irinotecan plus bevacizumab: A case report and review of the literature

Shimazaki,Jiro; Motohashi,Gyo; Nishida,Kiyotaka; Tabuchi,Takanobu; Ubukata,Hideyuki; Tabuchi,Takafumi

doi:10.3892/ol.2014.1939

Complete response of lung metastases from rectal cancer to combination first‑line therapy of S‑1 and irinotecan plus bevacizumab: A case report and review of the literature

Authors:
- Jiro Shimazaki
- Gyo Motohashi
- Kiyotaka Nishida
- Takanobu Tabuchi
- Hideyuki Ubukata
- Takafumi Tabuchi
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Ibaraki Medical Center, Tokyo Medical University, Ami, Ibaraki 300‑0395, Japan
Published online on: March 5, 2014 https://doi.org/10.3892/ol.2014.1939
Pages: 1455-1458

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This report presents the case of a 72‑year‑old male who had undergone abdominoperineal resection following a diagnosis of lower rectal cancer with multiple lung metastases. Pathologically, the resected specimen exhibited advanced rectal cancer with regional lymphoid metastases and was classified as stage IV disease. S‑1 and irinotecan (IRIS) plus bevacizumab combination therapy was used to treat the lung metastases following the surgery. S‑1 (100 mg/body) was administered orally on days 1‑14 of a 28‑day cycle, and irinotecan (125 mg/m2) and bevacizumab (7.5 mg/kg) were administered by intravenous infusion on days 1 and 15. Computed tomography revealed a marked decrease in the size of the metastases following three therapeutic courses, and no lung metastases or new lesions were detected following nine therapeutic courses. The response was declared clinically complete. The patient refused additional treatment following nine therapeutic courses, and there was no recurrence 36 months after the final course of therapy. This case demonstrates the efficacy of IRIS plus bevacizumab as a first‑line combination therapy against lung metastases of rectal cancer.

View Figures

View References

1	Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 22:1209–1214. 2004. View Article : Google Scholar
2	Watanabe T, Itabashi M, Shimada Y, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	Muro K, Boku N, Shimada Y, et al: Irinotecan plus S-1 (IRIS) versus fluorouracil and folininc acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 11:853–860. 2010. View Article : Google Scholar
4	Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 23:4866–4875. 2005.PubMed/NCBI
5	Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar
6	Choi YH, Kim TW, Kim KP, et al: A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: Influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. Oncology. 82:290–297. 2012. View Article : Google Scholar
7	Kaneko J, Isogai J, Aoyagi H, et al: A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy. Gan To Kagaku Ryoho. 37:2576–2578. 2010.(In Japanese).
8	Ueda S, Minami Y, Hara Y, Kawano T and Maekawa K: A case of recurrent rectal cancer with multiple lung metastases successfully treated with S-1 and CPT-11 combination chemotherapy. Gan To Kagaku Ryoho. 36:1725–1727. 2009.(In Japanese).
9	Samejima J, Iwasaki H, Hatori S, et al: Effectiveness of S-1 plus CPT-11 therapy for an elderly patient with recurrent colon cancer. Gan To Kagaku Ryoho. 36:1371–1373. 2009.(In Japanese).
10	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; NY: 2009
11	Schmoll HJ, Van Cutsem E, Stein A, et al: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 23:2479–2516. 2012. View Article : Google Scholar
12	Komatsu Y, Yuki S, Sogabe S, et al: Phase II study of combined chemotheraphy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrence or advanced colorectal cancer. Acta Oncol. 51:867–872. 2012. View Article : Google Scholar
13	Kato S, Andoh H, Gamoh M, et al: Safety verification trial of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients. Oncology. 83:101–107. 2012.PubMed/NCBI
14	Yamada Y, Yamaguchi T, Matsumoto H, et al: Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs. 30:1690–1696. 2012. View Article : Google Scholar
15	Goya T, Miyazawa N, Kondo H, Tsuchiya R, Naruke T and Suemasu K: Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer. 64:1418–1421. 1989.PubMed/NCBI
16	McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW and Ginsberg RJ: Lung resection for colorectal metastases. 10-year results. Arch Surg. 127:1403–1406. 1992.PubMed/NCBI
17	Ike H, Shimada H, Ohki S, Togo S, Yamaguchi S and Ichikawa Y: Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum. 45:468–473. 2002. View Article : Google Scholar : PubMed/NCBI
18	Farid M, Chowbay B, Chen X, et al: Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. Cancer Chemother Pharmacol. 70:141–150. 2012. View Article : Google Scholar : PubMed/NCBI
19	Matsuo K, Higuchi M, Sasaki Y, et al: Analysis of a case of oxaliplatin - induced persistence sensory neuropathy. Gan To Kagaku Ryoho. 37:551–554. 2010.(In Japanese).